|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Travis WD: Pathology of lung cancer. Clin
Chest Med. 32:669–692. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reck M, Heigener DF, Mok T, Soria JC and
Rabe KF: Management of non-small-cell lung cancer: Recent
developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hobert O: Gene regulation by transcription
factors and microRNAs. Science. 319:1785–1786. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fukumoto I, Hanazawa T, Kinoshita T,
Kikkawa N, Koshizuka K, Goto Y, Nishikawa R, Chiyomaru T, Enokida
H, Nakagawa M, et al: MicroRNA expression signature of oral
squamous cell carcinoma: Functional role of microRNA-26a/b in the
modulation of novel cancer pathways. Br J Cancer. 112:891–900.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fukumoto I, Kinoshita T, Hanazawa T,
Kikkawa N, Chiyomaru T, Enokida H, Yamamoto N, Goto Y, Nishikawa R,
Nakagawa M, et al: Identification of tumour suppressive
microRNA-451a in hypopharyngeal squamous cell carcinoma based on
microRNA expression signature. Br J Cancer. 111:386–394. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Matsushita R, Seki N, Chiyomaru T,
Inoguchi S, Ishihara T, Goto Y, Nishikawa R, Mataki H, Tatarano S,
Itesako T, et al: Tumour-suppressive microRNA-144-5p directly
targets CCNE1/2 as potential prognostic markers in bladder cancer.
Br J Cancer. 113:282–289. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goto Y, Kojima S, Nishikawa R, Enokida H,
Chiyomaru T, Kinoshita T, Nakagawa M, Naya Y, Ichikawa T and Seki
N: The microRNA-23b/27b/24-1 cluster is a disease progression
marker and tumor suppressor in prostate cancer. Oncotarget.
5:7748–7759. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mataki H, Enokida H, Chiyomaru T, Mizuno
K, Matsushita R, Goto Y, Nishikawa R, Higashimoto I, Samukawa T,
Nakagawa M, et al: Downregulation of the microRNA-1/133a cluster
enhances cancer cell migration and invasion in lung-squamous cell
carcinoma via regulation of Coronin1C. J Hum Genet. 60:53–61. 2015.
View Article : Google Scholar
|
|
13
|
Mataki H, Seki N, Chiyomaru T, Enokida H,
Goto Y, Kumamoto T, Machida K, Mizuno K, Nakagawa M and Inoue H:
Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR
oncogenic signaling in lung squamous cell carcinoma. Int J Oncol.
46:1039–1050. 2015.
|
|
14
|
Goto Y, Kurozumi A, Enokida H, Ichikawa T
and Seki N: Functional significance of aberrantly expressed
microRNAs in prostate cancer. Int J Urol. 22:242–252. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yoshino H, Seki N, Itesako T, Chiyomaru T,
Nakagawa M and Enokida H: Aberrant expression of microRNAs in
bladder cancer. Nat Rev Urol. 10:396–404. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kikkawa N, Hanazawa T, Fujimura L, Nohata
N, Suzuki H, Chazono H, Sakurai D, Horiguchi S, Okamoto Y and Seki
N: miR-489 is a tumour-suppressive miRNA target PTPN11 in
hypopharyngeal squamous cell carcinoma (HSCC). Br J Cancer.
103:877–884. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fuse M, Kojima S, Enokida H, Chiyomaru T,
Yoshino H, Nohata N, Kinoshita T, Sakamoto S, Naya Y, Nakagawa M,
et al: Tumor suppressive microRNAs (miR-222 and miR-31) regulate
molecular pathways based on microRNA expression signature in
prostate cancer. J Hum Genet. 57:691–699. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shepherd FA, Crowley J, Van Houtte P,
Postmus PE, Carney D, Chansky K, Shaikh Z and Goldstraw P:
International Association for the Study of Lung Cancer
International Staging Committee and Participating Institutions: The
International Association for the Study of Lung Cancer lung cancer
staging project: Proposals regarding the clinical staging of small
cell lung cancer in the forthcoming (seventh) edition of the tumor,
node, metastasis classification for lung cancer. J Thorac Oncol.
2:1067–1077. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weaver VM, Petersen OW, Wang F, Larabell
CA, Briand P, Damsky C and Bissell MJ: Reversion of the malignant
phenotype of human breast cells in three-dimensional culture and in
vivo by integrin blocking antibodies. J Cell Biol. 137:231–245.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bissell MJ and Radisky D: Putting tumours
in context. Nat Rev Cancer. 1:46–54. 2001. View Article : Google Scholar
|
|
21
|
Paszek MJ and Weaver VM: The tension
mounts: Mechanics meets morphogenesis and malignancy. J Mammary
Gland Biol Neoplasia. 9:325–342. 2004. View Article : Google Scholar
|
|
22
|
Paszek MJ, Zahir N, Johnson KR, Lakins JN,
Rozenberg GI, Gefen A, Reinhart-King CA, Margulies SS, Dembo M,
Boettiger D, et al: Tensional homeostasis and the malignant
phenotype. Cancer Cell. 8:241–254. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kinoshita T, Hanazawa T, Nohata N, Kikkawa
N, Enokida H, Yoshino H, Yamasaki T, Hidaka H, Nakagawa M, Okamoto
Y, et al: Tumor suppressive microRNA-218 inhibits cancer cell
migration and invasion through targeting laminin-332 in head and
neck squamous cell carcinoma. Oncotarget. 3:1386–1400. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kinoshita T, Nohata N, Hanazawa T, Kikkawa
N, Yamamoto N, Yoshino H, Itesako T, Enokida H, Nakagawa M, Okamoto
Y, et al: Tumour-suppressive microRNA-29s inhibit cancer cell
migration and invasion by targeting laminin-integrin signalling in
head and neck squamous cell carcinoma. Br J Cancer. 109:2636–2645.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nishikawa R, Goto Y, Kojima S, Enokida H,
Chiyomaru T, Kinoshita T, Sakamoto S, Fuse M, Nakagawa M, Naya Y,
et al: Tumor-suppressive microRNA-29s inhibit cancer cell migration
and invasion via targeting LAMC1 in prostate cancer. Int J Oncol.
45:401–410. 2014.PubMed/NCBI
|
|
26
|
Wang Y, Zhang X, Li H, Yu J and Ren X: The
role of miRNA-29 family in cancer. Eur J Cell Biol. 92:123–128.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nishikawa R, Chiyomaru T, Enokida H,
Inoguchi S, Ishihara T, Matsushita R, Goto Y, Fukumoto I, Nakagawa
M and Seki N: Tumour-suppressive microRNA-29s directly regulate
LOXL2 expression and inhibit cancer cell migration and invasion in
renal cell carcinoma. FEBS Lett. 589:2136–2145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yamamoto N, Kinoshita T, Nohata N, Yoshino
H, Itesako T, Fujimura L, Mitsuhashi A, Usui H, Enokida H, Nakagawa
M, et al: Tumor-suppressive microRNA-29a inhibits cancer cell
migration and invasion via targeting HSP47 in cervical squamous
cell carcinoma. Int J Oncol. 43:1855–1863. 2013.PubMed/NCBI
|
|
29
|
Mott JL, Kurita S, Cazanave SC, Bronk SF,
Werneburg NW and Fernandez-Zapico ME: Transcriptional suppression
of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J
Cell Biochem. 110:1155–1164. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu DW, Hsu NY, Wang YC, Lee MC, Cheng YW,
Chen CY and Lee H: c-Myc suppresses microRNA-29b to promote tumor
aggressiveness and poor outcomes in non-small cell lung cancer by
targeting FHIT. Oncogene. 34:2072–2082. 2015. View Article : Google Scholar
|
|
31
|
Chou J, Lin JH, Brenot A, Kim JW, Provot S
and Werb Z: GATA3 suppresses metastasis and modulates the tumour
micro-environment by regulating microRNA-29b expression. Nat Cell
Biol. 15:201–213. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Maurer B, Stanczyk J, Jüngel A,
Akhmetshina A, Trenkmann M, Brock M, Kowal-Bielecka O, Gay RE,
Michel BA, Distler JH, et al: MicroRNA-29, a key regulator of
collagen expression in systemic sclerosis. Arthritis Rheum.
62:1733–1743. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Roderburg C, Urban GW, Bettermann K, Vucur
M, Zimmermann H, Schmidt S, Janssen J, Koppe C, Knolle P, Castoldi
M, et al: Micro-RNA profiling reveals a role for miR-29 in human
and murine liver fibrosis. Hepatology. 53:209–218. 2011. View Article : Google Scholar
|
|
34
|
Matsuo M, Nakada C, Tsukamoto Y, Noguchi
T, Uchida T, Hijiya N, Matsuura K and Moriyama M: MiR-29c is
down-regulated in gastric carcinomas and regulates cell
proliferation by targeting RCC2. Mol Cancer. 12:152013. View Article : Google Scholar
|
|
35
|
Barker HE, Cox TR and Erler JT: The
rationale for targeting the LOX family in cancer. Nat Rev Cancer.
12:540–552. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kagan HM and Li W: Lysyl oxidase:
Properties, specificity, and biological roles inside and outside of
the cell. J Cell Biochem. 88:660–672. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vadasz Z, Kessler O, Akiri G,
Gengrinovitch S, Kagan HM, Baruch Y, Izhak OB and Neufeld G:
Abnormal deposition of collagen around hepatocytes in Wilson's
disease is associated with hepatocyte specific expression of lysyl
oxidase and lysyl oxidase like protein-2. J Hepatol. 43:499–507.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim YM, Kim EC and Kim Y: The human lysyl
oxidase-like 2 protein functions as an amine oxidase toward
collagen and elastin. Mol Biol Rep. 38:145–149. 2011. View Article : Google Scholar
|
|
39
|
Erler JT and Weaver VM: Three-dimensional
context regulation of metastasis. Clin Exp Metastasis. 26:35–49.
2009. View Article : Google Scholar :
|
|
40
|
Kauppila S, Stenbäck F, Risteli J, Jukkola
A and Risteli L: Aberrant type I and type III collagen gene
expression in human breast cancer in vivo. J Pathol. 186:262–268.
1998. View Article : Google Scholar
|
|
41
|
Mackie EJ, Chiquet-Ehrismann R, Pearson
CA, Inaguma Y, Taya K, Kawarada Y and Sakakura T: Tenascin is a
stromal marker for epithelial malignancy in the mammary gland. Proc
Natl Acad Sci USA. 84:4621–4625. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhu GG, Risteli L, Mäkinen M, Risteli J,
Kauppila A and Stenbäck F: Immunohistochemical study of type I
collagen and type I pN-collagen in benign and malignant ovarian
neoplasms. Cancer. 75:1010–1017. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kasashima H, Yashiro M, Kinoshita H,
Fukuoka T, Morisaki T, Masuda G, Sakurai K, Kubo N, Ohira M and
Hirakawa K: Lysyl oxidase-like 2 (LOXL2) from stromal fibroblasts
stimulates the progression of gastric cancer. Cancer Lett.
354:438–446. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ahn SG, Dong SM, Oshima A, Kim WH, Lee HM,
Lee SA, Kwon SH, Lee JH, Lee JM, Jeong J, et al: LOXL2 expression
is associated with invasiveness and negatively influences survival
in breast cancer patients. Breast Cancer Res Treat. 141:89–99.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Peinado H, Moreno-Bueno G, Hardisson D,
Pérez-Gómez E, Santos V, Mendiola M, de Diego JI, Nistal M,
Quintanilla M, Portillo F, et al: Lysyl oxidase-like 2 as a new
poor prognosis marker of squamous cell carcinomas. Cancer Res.
68:4541–4550. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Schietke R, Warnecke C, Wacker I, Schödel
J, Mole DR, Campean V, Amann K, Goppelt-Struebe M, Behrens J,
Eckardt KU, et al: The lysyl oxidases LOX and LOXL2 are necessary
and sufficient to repress E-cadherin in hypoxia: Insights into
cellular transformation processes mediated by HIF-1. J Biol Chem.
285:6658–6669. 2010. View Article : Google Scholar :
|
|
48
|
Moon HJ, Finney J, Xu L, Moore D, Welch DR
and Mure M: MCF-7 cells expressing nuclear associated lysyl
oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal
transition (EMT) phenotype and are highly invasive in vitro. J Biol
Chem. 288:30000–30008. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Peng L, Ran YL, Hu H, Yu L, Liu Q, Zhou Z,
Sun YM, Sun LC, Pan J, Sun LX, et al: Secreted LOXL2 is a novel
therapeutic target that promotes gastric cancer metastasis via the
Src/FAK pathway. Carcinogenesis. 30:1660–1669. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Barry-Hamilton V, Spangler R, Marshall D,
McCauley S, Rodriguez HM, Oyasu M, Mikels A, Vaysberg M, Ghermazien
H, Wai C, et al: Allosteric inhibition of lysyl oxidase-like-2
impedes the development of a pathologic microenvironment. Nat Med.
16:1009–1017. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Voloshenyuk TG, Landesman ES, Khoutorova
E, Hart AD and Gardner JD: Induction of cardiac fibroblast lysyl
oxidase by TGF-β1 requires PI3K/Akt, Smad3, and MAPK signaling.
Cytokine. 55:90–97. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Roy R, Polgar P, Wang Y, Goldstein RH,
Taylor L and Kagan HM: Regulation of lysyl oxidase and
cyclooxygenase expression in human lung fibroblasts: Interactions
among TGF-beta, IL-1 beta, and prostaglandin E. J Cell Biochem.
62:411–417. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Tan J, Tong BD, Wu YJ and Xiong W:
MicroRNA-29 mediates TGFβ1-induced extracellular matrix synthesis
by targeting wnt/β-catenin pathway in human orbital fibroblasts.
Int J Clin Exp Pathol. 7:7571–7577. 2014.
|
|
54
|
Yang T, Liang Y, Lin Q, Liu J, Luo F, Li
X, Zhou H, Zhuang S and Zhang H: miR-29 mediates TGFβ1-induced
extracellular matrix synthesis through activation of PI3K-AKT
pathway in human lung fibroblasts. J Cell Biochem. 114:1336–1342.
2013. View Article : Google Scholar
|
